Beyond the Blood-Brain Barrier: Skull Bone Marrow TSPO Overexpression as a Novel Biomarker for Multiple Sclerosis Progression
Posted inNeurology news Radiology

Beyond the Blood-Brain Barrier: Skull Bone Marrow TSPO Overexpression as a Novel Biomarker for Multiple Sclerosis Progression

**Refining Content Structure** I'm now deeply immersed in the content. I've drafted the introduction, designed to capture attention and set the scene. I am expanding on the key findings, including correlations, and the clinical implications. I am paying close attention to the structural integrity to ensure it adheres to professional standards and the tone of the target audience. A landmark study reveals that skull bone marrow inflammation, measured via TSPO PET imaging, is significantly elevated in secondary progressive multiple sclerosis and correlates with clinical disability, suggesting a new paradigm for monitoring disease progression beyond traditional neuroimaging.
Low‑Dose Interleukin‑2 Expands Regulatory T Cells and Modulates Biomarkers in Mild–Moderate Alzheimer’s Disease: Phase 2a Randomized Trial Shows Safety and Promising Signals
Posted inAllergy & Immunology Neurology news

Low‑Dose Interleukin‑2 Expands Regulatory T Cells and Modulates Biomarkers in Mild–Moderate Alzheimer’s Disease: Phase 2a Randomized Trial Shows Safety and Promising Signals

A phase 2a randomized trial found low‑dose IL‑2 given every 4 weeks was safe, expanded regulatory T cells, altered peripheral inflammatory mediators, increased CSF Aβ42, stabilized NfL, and trended toward slower cognitive decline in mild–moderate AD.